Immuneering (IMRX) EPS (Weighted Average and Diluted) (2020 - 2026)
Immuneering (IMRX) recorded quarterly EPS (Weighted Average and Diluted) of -$0.21 in Q1 2026, down 200.0% quarter-over-quarter from -$0.07 in Q4 2025, and up 50.0% on a YoY basis from -$0.14 in Q1 2025.
Immuneering (IMRX) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Immuneering's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.21 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 50.0% year-over-year to -$0.21; the TTM figure through Mar 2026 stood at -$1.06 (up 46.19% YoY), while the FY2025 annual figure was -$1.27, up 37.75% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.21 for Q1 2026 at Immuneering, down from -$0.07 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q4 2025 to a low of -$0.59 in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.43 across 5 years, with a median of -$0.47 in 2024.
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) plunged 900.0% in 2022, then surged 88.14% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.5 in 2022, then slipped by 4.0% to -$0.52 in 2023, then slipped by 13.46% to -$0.59 in 2024, then soared by 88.14% to -$0.07 in 2025, then plunged by 200.0% to -$0.21 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.21 (Q1 2026), -$0.07 (Q4 2025), and -$0.38 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | -0.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.21 |
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -0.40 |
| Mar 31, 2025 | -0.42 |
| Dec 31, 2024 | -0.59 |
| Sep 30, 2024 | -0.49 |
| Jun 30, 2024 | -0.47 |
| Mar 31, 2024 | -0.49 |
| Dec 31, 2023 | -0.52 |
| Sep 30, 2023 | -0.43 |
| Jun 30, 2023 | -0.43 |
| Mar 31, 2023 | -0.51 |
| Dec 31, 2022 | -0.50 |
| Sep 30, 2022 | -0.49 |
| Jun 30, 2022 | -0.44 |
| Mar 31, 2022 | -0.49 |
| Dec 31, 2021 | -0.05 |
| Sep 30, 2021 | -0.47 |
| Jun 30, 2021 | -1.61 |